Long-term treatment-free remission (TFR) following frontline (1L) nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom 144-wk results.
2018 ◽
Vol 36
(15_suppl)
◽
pp. 7063-7063
2018 ◽
Vol 36
(15_suppl)
◽
pp. 7003-7003
◽
2018 ◽
Vol 18
◽
pp. S222
◽
2018 ◽
Vol 18
◽
pp. S226
◽
2019 ◽
Vol 41
(4)
◽
pp. 329-334
◽
Keyword(s):
Keyword(s):